These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23406552)

  • 21. Bevacizumab in the treatment of ovarian cancer.
    Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
    Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
    Aravantinos G; Pectasides D
    J Ovarian Res; 2014; 7():57. PubMed ID: 24864163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of bevacizumab in advanced epithelial ovarian cancer.
    Kroep JR; Nortier JW
    Curr Pharm Des; 2012; 18(25):3775-83. PubMed ID: 22591420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiogenesis as a target for the treatment of ovarian cancer.
    Shaw D; Clamp A; Jayson GC
    Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of antiangiogenic therapies for ovarian cancer.
    Markowska A; Lubin J; Madry R; Markowska J
    Eur J Gynaecol Oncol; 2013; 34(4):303-6. PubMed ID: 24020134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab and its use in epithelial ovarian cancer.
    Matulonis UA
    Future Oncol; 2011 Mar; 7(3):365-79. PubMed ID: 21323425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer.
    Khosravi-Shahi P; Cabezon-Gutierrez L
    Anticancer Agents Med Chem; 2012 Oct; 12(8):982-7. PubMed ID: 22263801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.
    Markman M
    Ann Oncol; 2011 Dec; 22 Suppl 8():viii69-viii71. PubMed ID: 22180406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
    J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.
    Chan JK; Herzog TJ; Hu L; Monk BJ; Kiet T; Blansit K; Kapp DS; Yu X
    Oncologist; 2014 May; 19(5):523-7. PubMed ID: 24721817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment.
    Aigner J; Bischofs E; Hallscheidt P; Sohn C; Schneeweiss A; Eichbaum M
    Anticancer Drugs; 2011 Nov; 22(10):1030-3. PubMed ID: 21970854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab and ovarian cancer.
    Lai GG; Penson RT
    Drugs Today (Barc); 2011 Sep; 47(9):669-81. PubMed ID: 21971541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study.
    Chase DM; Sill MW; Monk BJ; Chambers MD; Darcy KM; Han ES; Buening BJ; Sorosky JI; Fruehauf JP; Burger RA
    Gynecol Oncol; 2012 Sep; 126(3):375-80. PubMed ID: 22683587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab in ovarian cancer.
    Korn EL; Freidlin B; Abrams JS
    N Engl J Med; 2012 Mar; 366(13):1256; author reply 1257-8. PubMed ID: 22455428
    [No Abstract]   [Full Text] [Related]  

  • 37. Bevacizumab in ovarian cancer.
    Copur MS; Obermiller AM; Ramaekers R
    N Engl J Med; 2012 Mar; 366(13):1256-7; author reply 1257-8. PubMed ID: 22455429
    [No Abstract]   [Full Text] [Related]  

  • 38. Bevacizumab in ovarian cancer.
    Mountzios G; Pentheroudakis G
    N Engl J Med; 2012 Mar; 366(13):1257; author reply 1258. PubMed ID: 22455430
    [No Abstract]   [Full Text] [Related]  

  • 39. [Chemotherapy in epithelial ovarian cancer].
    Tazi Y; Pautier P; Leary A; Lhomme C
    Gynecol Obstet Fertil; 2013 Oct; 41(10):611-6. PubMed ID: 24094667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epithelial ovarian cancer: focus on targeted therapy.
    Pliarchopoulou K; Pectasides D
    Crit Rev Oncol Hematol; 2011 Jul; 79(1):17-23. PubMed ID: 20674385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.